Physician profile
Robert G Bashuk
NPI 1316940547
$3,823.56
in general payments reported to CMS, 2019-2025
40 companies · $788 in 2025
The $788 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $48.40 · 2021: $753 · 2022: $934 · 2023: $354 · 2024: $397 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,444 · Education: $94.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,443.75 |
| Education | $94.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $561.86 | 2021-2025 | Ubrelvy, Qulipta |
| Pfizer INC. | $375.80 | 2023-2025 | |
| Lundbeck LLC | $303.08 | 2021-2025 | Vyepti, Rexulti |
| Janssen Pharmaceuticals, INC | $236.02 | 2021-2025 | |
| Genentech USA, INC. | $169.73 | 2019-2025 | Ocrevus Zunovo |
| Janssen Biotech, INC. | $167.77 | 2025 | |
| Harmony Biosciences LLC | $157.93 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $149.38 | 2022 | |
| Upsher-Smith Laboratories LLC | $142.78 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $127.39 | 2021-2022 | |
| Amgen INC. | $110.08 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $110.01 | 2021-2023 | Soliris |
| Biogen, INC. | $91.34 | 2019-2022 | |
| Greenwich Biosciences, INC. | $89.15 | 2019-2021 | |
| Lilly USA, LLC | $86.30 | 2020-2024 | Emgality |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $85.99 | 2025 | Symbravo |
| Ucb, INC. | $83.77 | 2020-2022 | |
| Celgene Corporation | $82.36 | 2021-2022 | |
| Eisai INC. | $75.99 | 2025 | |
| Nevro Corp. | $71.27 | 2019 | |
| Supernus Pharmaceuticals, INC. | $65.01 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $64.15 | 2022-2023 | Nuplazid |
| Novartis Pharmaceuticals Corporation | $52.58 | 2019 | |
| Kyowa Kirin, INC. | $49.45 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $49.15 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $37.54 | 2021-2025 | Austedo Xr |
| Acorda Therapeutics, INC | $27.39 | 2019 | |
| Genzyme Corporation | $20.80 | 2022 | |
| Jazz Pharmaceuticals INC. | $20.03 | 2022 | |
| Ge Healthcare | $19.17 | 2019 | |
| Avanir Pharmaceuticals, INC. | $17.63 | 2019 | |
| Adamas Pharmaceuticals, INC. | $17.11 | 2021 | |
| Zyla Life Sciences, INC. | $14.73 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.55 | 2019 | |
| Boston Scientific Corporation | $14.19 | 2019 | |
| Almatica Pharma LLC | $13.63 | 2021 | |
| Allergan, INC. | $12.83 | 2019 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Sk Life Science, INC. | $11.88 | 2021 | |
| Merz North America, INC. | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bashuk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.